You are here
Angiochem has moved beyond physiological and scientific barriers to discover and develop a new class of pharmaceuticals. These breakthrough products are designed to cross the blood-brain barrier to treat primary brain cancer, brain metastases, lysosomal storage diseases, pain, and other unmet medical needs.
Treating primary brain cancers and cancers that have metastasized to the brain has proven challenging. However, in early-stage clinical trials, ANG1005 has demonstrated anti-cancer activity. More >
Current therapies for managing moderate to severe pain from cancer, post-operative surgery, and neuropathic pain have significant limitations. But ANG2002 has the potential to be a first in class analgesic drug, without the side effects of opiates. More >
Lysosomal storage diseases (LSDs) comprise a large group of rare inherited disorders, including Tay Sachs Disease, Fabry Disease, Gaucher’s Disease, Pompe Disease, Hunter syndrome and other mucopolysaccharidosis (MPS). More >